Lenacapavir is a long-acting HIV capsid inhibitor disrupting viral replication at multiple stages.  The drug is administered biannually via subcutaneous injection, it's effective for multidrug-resistant HIV. Its unique mechanism improves adherence and simplifies regimens. Common side effects include injection site reactions. Ongoing studies explore its use in prevention, offering hope for better HIV management and PrEP strategies.